

Rhythm Biosciences enters strategic co-marketing partnership with Know Your Lemons Foundation to expand access to early breast cancer screening

Highlights

- Rhythm has entered an important co-marketing relationship to make geneType[™] available on the *Know Your Lemons* mobile application reaching hundreds of thousands of women in the US and Australia;
- This partnership aligns with Breast Cancer Awareness Month in October, supporting proactive healthcare for women; and
- A major milestone in elevating geneType[™] brand awareness and commercialisation.

Melbourne, Australia, 28th August 2025: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX:RHY), a transformative, predictive cancer diagnostics technology company is pleased to announce it has entered a new co-marketing agreement with the *Know Your Lemons Foundation* (KYL www.knowyourlemons.org), a leading global non-profit organisation dedicated to breast cancer education and early detection.

The agreement ensures that Rhythm's geneType[™] Breast Cancer Risk Assessment Test will now be actively promoted through the *Know Your Lemons at Work* breast health benefit employee community, reaching hundreds of thousands of women in the United States. While KYL has previously engaged with Genetic Technologies Limited to access geneType[™], Rhythm has formalised and re-established the partnership under its stewardship and is actively collaborating on the rollout, which includes blogs, webinars and education that will promote awareness and uptake of geneType[™]. The collaboration represents an important step in Rhythm's commercialisation strategy, positioning geneType[™] as a proactive tool in breast cancer risk assessment, complementing existing screening pathways.

About Know Your Lemons Foundation

- KYL has achieved a global reach of more than 2 billion people online, with education programs delivered in-person in over 75 countries.
- More than 1,300 trained educators ("Lemonistas") deliver KYL programs.
- KYL empowers women to understand their breast health, risk factors and screening options.

Strategic Timing – Breast Cancer Awareness Month

This new partnership aligns with Breast Cancer Awareness Month in October, a key opportunity to highlight the importance of early detection. Rhythm and KYL will leverage this global health campaign to promote proactive breast health education and geneType[™] awareness.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

Directors

| | |
|-----------------|-------------------------|
| Otto Buttula | Non-Executive Chairman |
| Sue MacLeman | Non-Executive Director |
| Gavin Fox-Smith | Non-Executive Director |
| David Atkins | CEO & Managing Director |

Commentary

Rhythm CEO David Atkins said:

“This agreement represents an important acceleration of our commercial activity with Know Your Lemons. While the informal relationship existed historically, Rhythm has entered a formal agreement in which both parties will have a clear focus on execution and having an impact on the KYL community. By activating geneType™ through KYL’s app, we can reach millions of women in the U.S. and Australia, supporting proactive health decisions and ultimately improving early detection outcomes.”

KYL Founder and CEO Corrine Ellsworth Beaumont said:

“Our mission has always been to make breast health education accessible and actionable for everyone. Incorporating Rhythm’s geneType™ test into our app gives our community another valuable tool to understand and manage their breast cancer risk.”

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience’s simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia’s CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform’s multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.